scholarly journals Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

2012 ◽  
Vol 67 (6) ◽  
pp. 1265-1272 ◽  
Author(s):  
Emily Y. Chu ◽  
Karolyn A. Wanat ◽  
Christopher J. Miller ◽  
Ravi K. Amaravadi ◽  
Leslie A. Fecher ◽  
...  
Keyword(s):  
Side Effects ◽  
Braf Inhibitor ◽  
Inhibitor Therapy ◽  
Cutaneous Side Effects ◽  
Clinicopathologic Study

Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19017-e19017 ◽  
Author(s):  
Simone M. Goldinger ◽  
Jeannine Desiree Rinderknecht ◽  
Benedetta Belloni ◽  
Nina Eggmann ◽  
Reinhard Dummer
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
Cell Carcinoma ◽  
Braf Inhibitor ◽  
Primary Melanoma ◽  
Stage Iv ◽  
Invasive Squamous Cell Carcinoma ◽  
Single Center ◽  
Skin Reactions ◽  
Cutaneous Side Effects

e19017 Background: V is a potent BRAF inhibitor with significant impact on progression-free and overall survival in mM pts. cAE are very common. This single-center observation analyses the clinical and histological spectrum of this new class-specific cAE in 28 pts treated with V in different clinical trials. Methods: 28 mM pts stage IV were treated with V 960mg b.i.d. in local ethic committees approved clinical trials. Occurring side effects were collected and documented prospectively. 65 biopsies were analysed. cAE were classified by reaction pattern as inflammatory diseases, hair and nail changes, keratinocytic proliferations, melanocytic disorders and proliferations. Results: V was well tolerated; in 2 pts dose reduction was necessary due to arthragia. 26/28 pts (93%) experienced cAE. UVA dependent photosensitivity and maculopapular exanthema were observed in 16 and 14 pts respectively. The histology of the rash demonstrated alteration of eccrine and follicular structures with mild inflammation and no increased keratinocytic apoptosis, thus differing from the rash of MEK inhibitors. Pruritus was observed in 8, folliculitis in 5, and burning feet in 3 pts. Hair thinning and alopecia occurred in 8 pts, 2 pts presented with curly hair. Follicular hyperkeratosis and acanthopapilloma were common skin reactions (n=12/n=13), as well as plantar hyperkeratosis (n=4), keratoacanthoma (n=5) and invasive squamous cell carcinoma (n=4). Histology of the acanthopapilloma (n=39) showed marked hyperkeratosis and acanthosis with koilocytes and mitosis, suggesting viral association. Single observations of morbus Bowen, Bowen carcinoma, basal cell carcinoma and a warty dyskeratoma were documented. 1 pt developed after more than 4 months of therapy a secondary primary melanoma on the capillitium (BRAF and RAS wildtype). Conclusions: V has a broad and particular cAE profile involving epidermis and adnexals. Regular skin examination by experienced dermatologists is crucial under V to detect and treat the possible side effects promptly. The treatment is very well tolerated but can have an impact in quality of life; ergo the pts have to be well informed. UVA optimized photoprotection is essential.

scholarly journals Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

2013 ◽  
Vol 24 (6) ◽  
pp. 1691-1697 ◽  
Author(s):  
L. Boussemart ◽  
E. Routier ◽  
C. Mateus ◽  
K. Opletalova ◽  
G. Sebille ◽  
...  
Keyword(s):  
Side Effects ◽  
Prospective Study ◽  
Braf Inhibitor ◽  
Cutaneous Side Effects

Cutaneous Side Effects in 19 Lung Cancer Patients Treated with Gefitinib (Iressa)

2004 ◽  
Vol 66 (6) ◽  
pp. 602-607 ◽  
Author(s):  
Miho UCHIHIRA ◽  
Takahiro EJIMA ◽  
Takao UCHIHIRA ◽  
Jun ARAKI ◽  
Toshiaki KAMEI
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Cutaneous Side Effects ◽  
Lung Cancer Patients

scholarly journals Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Bilgen Gençler ◽  
Müzeyyen Gönül
Keyword(s):  
Side Effects ◽  
Metastatic Melanoma ◽  
Mapk Pathway ◽  
Case Reports ◽  
Mitogen Activated Protein Kinase ◽  
Braf V600e ◽  
Braf Inhibitors ◽  
Braf Mutations ◽  
Cutaneous Side Effects ◽  
Downstream Signaling

The incidence of melanoma has recently been increasing. BRAF mutations have been found in 40–60% of melanomas. The increased activity of BRAF V600E leads to the activation of downstream signaling through the mitogen-activated protein kinase (MAPK) pathway, which plays a key role as a regulator of cell growth, differentiation, and survival. The use of BRAF inhibitors in metastatic melanoma with BRAF mutation ensures clinical improvement of the disease. Vemurafenib and dabrafenib are two selective BRAF inhibitors approved by the Food and Drug Administration (FDA). Both drugs are well tolerated and successfully used in clinical practice. However, some adverse reactions have been reported in patients in the course of treatment. Cutaneous side effects are the most common adverse events among them with a broad spectrum. Both the case reports and several original clinical trials reported cutaneous reactions during the treatment with BRAF inhibitors. In this review, the common cutaneous side effects of BRAF inhibitors in the treatment of metastatic melanoma with BRAF V600E mutation were reviewed.

Metastatic Hepatic Angiosarcoma and BRAF Inhibitor Therapy

2017 ◽  
Vol 03 (04) ◽  
Author(s):  
Shweta Gera ◽  
Mark Ettel ◽  
Gabriel Acosta Gonzalez ◽  
Melissa Wilson ◽  
Ruliang Xu
Keyword(s):  
Braf Inhibitor ◽  
Inhibitor Therapy ◽  
Hepatic Angiosarcoma

scholarly journals Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255716
Author(s):  
Náthali Felícia Mineiro dos Santos Garrett ◽  
Ana Cristina Carvalho da Costa ◽  
Elaine Barros Ferreira ◽  
Giovanni Damiani ◽  
Paula Elaine Diniz dos Reis ◽  
...  
Keyword(s):  
Systematic Review ◽  
Side Effects ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Cutaneous Toxicity ◽  
Cutaneous Side Effects ◽  
Final Sample

Background Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated. Objective To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy. Materials and methods We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data Results A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%). Conclusion The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors.

Sign in / Sign up

Export Citation Format

Share Document